This antibody is broadly reactive with human solid tumors, including embryonal tumors, carcinomas, sarcomas and brain tumors. It binds to a FG loop-dependent conformation on the B7-H3 molecule, a domain critical for its biologic function.
In early phase human clinical trials, radiolabeled burtomab is proven to prolong survival among high risk patients with solid tumors suffering from central nervous system (CNS) metastasis. It is also proven safe when injected intraperitoneally in young adults with desmoplastic small round cell tumor of the peritoneum.
The murine burtomab antibody has since been humanized, affinity matured and built into new generation antibody formats. Our 8H9 and Hu8H9 are promising agents for radioimmunotherapy of leptomeningeal metastases, Diffuse Intrinsic Pontine Glioma (DIPG), and malignant ascites.